Heart-type fatty acid binding protein and vascular endothelial growth factor: Cerebrospinal fluid biomarker candidates for Alzheimer's disease

European Archives of Psychiatry and Clinical Neuroscience

Volumn 263, Issue 7, 2013, Pages 553-560

  Guo, Liang Hao ^a   Alexopoulos, Panagiotis ^a   Perneczky, Robert ^a,b,c  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^b IMPERIAL COLLEGE LONDON   (United Kingdom)

^c WEST LONDON MENTAL HEALTH NHS TRUST   (United Kingdom)

Author keywords

Alzheimer's disease; Biomarker; Cerebrospinal fluid; Diagnosis; Proteomics

Indexed keywords

ALPHA FETOPROTEIN; AMYLOID BETA PROTEIN[1-42]; C REACTIVE PROTEIN; EOTAXIN; FATTY ACID BINDING PROTEIN; INTERLEUKIN 17; INTERLEUKIN 7; TAU PROTEIN; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND RECEPTOR 3; VASCULOTROPIN;

ADULT; AGED; AGING; ALZHEIMER DISEASE; ARTICLE; CEREBROSPINAL FLUID ANALYSIS; CLINICAL TRIAL; COGNITION; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MILD COGNITIVE IMPAIRMENT; MINI MENTAL STATE EXAMINATION; PREDICTIVE VALUE; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; PROTEOMICS; SENSITIVITY AND SPECIFICITY;

AGED; AGED, 80 AND OVER; AGING; ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; BIOLOGICAL MARKERS; DISEASE PROGRESSION; FATTY ACID-BINDING PROTEINS; FEMALE; HUMANS; MALE; MIDDLE AGED; MILD COGNITIVE IMPAIRMENT; PHOSPHORYLATION; PROTEOMICS; SENSITIVITY AND SPECIFICITY; TAU PROTEINS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84885182452     PISSN: 09401334     EISSN: 14338491     Source Type: Journal    
DOI: 10.1007/s00406-013-0405-4     Document Type: Article

References (49)

1. Benjamini Y, Hochberg Y (1995) Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Stat Soc Series B Stat Methodol 57:289-300
2. Bjerke M, Zetterberg H, Edman A, Blennow K, Wallin A, Andreasson U (2011) Cerebrospinal fluid matrix metalloproteinases and tissue inhibitor of metalloproteinases in combination with subcortical and cortical biomarkers in vascular dementia and Alzheimer's disease. J Alzheimers dis 27:665-676
3. Blasko I, Lederer W, Oberbauer H, Walch T, Kemmler G, Hinterhuber H, Marksteiner J, Humpel C (2006) Measurement of thirteen biological markers in CSF of patients with Alzheimer's disease and other dementias. Dement Geriatr Cogn Dis 21:9-15
4. Blennow K, Zetterberg H (2009) Cerebrospinal fluid biomarkers for Alzheimer's disease. J Alzheimers dis 18:413-417
5. Blennow K, Hampel H, Weiner M, Zetterberg H (2010) Cerebrospinal fluid and plasma biomarkers in Alzheimer disease. Nat Rev Neurol 6:131-144
6. Britschgi M, Rufibach K, Huang SL, Clark CM, Kaye JA, Li G, Peskind ER, Quinn JF, Galasko DR, Wyss-Coray T (2011) Modeling of pathological traits in Alzheimer's disease based on systemic extracellular signalling proteome. Mol Cell Proteomics 10:M111.008862
7. Burger S, Noack M, Kirazov LP, Kirazov EP, Naydenov CL, Kouznetsova E, Yafai Y, Schliebs R (2009) Vascular endothelial growth factor (vegf) affects processing of amyloid precursor protein and beta-amyloidogenesis in brain slice cultures derived from transgenic tg2576 mouse brain. Int J Dev Neurosci 27:517-523
8. Catelan D, Biggeri A (2010) Multiple testing in disease mapping and descriptive epidemiology. Geospat health 4:219-229
9. Cheon MS, Kim SH, Fountoulakis M, Lubec G (2003) Heart type fatty acid binding protein (h-fabp) is decreased in brains of patients with down syndrome and Alzheimer's disease. J neural transm Suppl 67:225-234
10. Chiasserini D, Parnetti L, Andreasson U, Zetterberg H, Giannandrea D, Calabresi P, Blennow K (2010) CSF levels of heart fatty acid binding protein are altered during early phases of Alzheimer's disease. J Alzheimers dis 22:1281-1288
11. Chin AL, Negash S, Hamilton R (2011) Diversity and disparity in dementia: the impact of ethnoracial differences in Alzheimer disease. Alzheimer Dis Assoc Disord 25:187-195
12. Craig-Schapiro R, Kuhn M, Xiong C, Pickering EH, Liu J, Misko TP, Perrin RJ, Bales KR, Soares H, Fagan AM, Holtzman DM (2011) Multiplexed immunoassay panel identifies novel CSF biomarkers for Alzheimer's disease diagnosis and prognosis. PLoS ONE 6:e18850
13. Guo LH, Alexopoulos P, Eisele T, Wagenpfeil S, Kurz A, Perneczky R (2012) The national institute on Aging-Alzheimer's association research criteria for mild cognitive impairment due to Alzheimer's disease: Predicting the outcome. Eur Arch Psychiatry Clin Neurosci. doi: 10.1007/s00406-012-0349-0
14. Hu WT, Chen-Plotkin A, Arnold SE, Grossman M, Clark CM, Shaw LM, McCluskey L, Elman L, Karlawish J, Hurtig HI, Siderowf A, Lee VM, Soares H, Trojanowski JQ (2010) Biomarker discovery for Alzheimer's disease, frontotemporal lobar degeneration, and Parkinson's disease. Acta Neuropathol 120:385-399
15. Hu WT, Chen-Plotkin A, Arnold SE, Grossman M, Clark CM, Shaw LM, Pickering E, Kuhn M, Chen Y, McCluskey L, Elman L, Karlawish J, Hurtig HI, Siderowf A, Lee VM, Soares H, Trojanowski JQ (2010) Novel csf biomarkers for Alzheimer's disease and mild cognitive impairment. Acta Neuropathol 119:669-678
16. Hulstaert F, Blennow K, Ivanoiu A, Schoonderwaldt HC, Riemenschneider M, De Deyn PP, Bancher C, Cras P, Wiltfang J, Mehta PD, Iqbal K, Pottel H, Vanmechelen E, Vanderstichele H (1999) Improved discrimination of ad patients using beta-amyloid(1-42) and tau levels in csf. Neurology 52:1555-1562
17. Jack CR Jr, Vemuri P, Wiste HJ, Weigand SD, Aisen PS, Trojanowski JQ, Shaw LM, Bernstein MA, Petersen RC, Weiner MW, Knopman DS (2011) Evidence for ordering of alzheimer disease biomarkers. Arch Neurol 68:1526-1535
18. Kalaria RN, Cohen DL, Premkumar DR, Nag S, LaManna JC, Lust WD (1998) Vascular endothelial growth factor in Alzheimer's disease and experimental cerebral ischemia. Brain Res Mol Brain Res 62:101-105
19. Kim S, Swaminathan S, Shen L, Risacher SL, Nho K, Foroud T, Shaw LM, Trojanowski JQ, Potkin SG, Huentelman MJ, Craig DW, Dechairo BM, Aisen PS, Petersen RC, Weiner MW, Saykin AJ (2011) Genome-wide association study of csf biomarkers a{beta}1-42, t-tau, and p-tau181p in the adni cohort. Neurology 76:69-79
20. Lescuyer P, Allard L, Hochstrasser DF, Sanchez JC (2005) Heart-fatty acid-binding protein as a marker for early detection of acute myocardial infarction and stroke. Mol diagn 9:1-7
21. Martins-de-Souza D (2010) Is the word 'biomarker' being properly used by proteomics research in neuroscience? Eur Arch Psychiatry Clin Neurosci 260:561-562
22. Matsui Y, Satoh K, Mutsukura K, Watanabe T, Nishida N, Matsuda H, Sugino M, Shirabe S, Eguchi K, Kataoka Y (2010) Development of an ultra-rapid diagnostic method based on heart-type fatty acid binding protein levels in the csf of cjd patients. Cell Mol Neurobiol 30:991-999
23. Mollenhauer B, Steinacker P, Bahn E, Bibl M, Brechlin P, Schlossmacher MG, Locascio JJ, Wiltfang J, Kretzschmar HA, Poser S, Trenkwalder C, Otto M (2007) Serum heart-type fatty acid-binding protein and cerebrospinal fluid tau: marker candidates for dementia with lewy bodies. Neurodegener dis 4:366-375
24. Morris JC, McKeel DW Jr, Fulling K, Torack RM, Berg L (1988) Validation of clinical diagnostic criteria for Alzheimer's disease. Ann Neurol 24:17-22
25. Ohrfelt A, Andreasson U, Simon A, Zetterberg H, Edman A, Potter W, Holder D, Devanarayan V, Seeburger J, Smith AD, Blennow K, Wallin A (2011) Screening for new biomarkers for subcortical vascular dementia and Alzheimer's disease. Dement geriatr cogn dis extra 1:31-42
26. Otto M, Lewczuk P, Wiltfang J (2008) Neurochemical approaches of cerebrospinal fluid diagnostics in neurodegenerative diseases. Methods 44:289-298
27. Pelsers MM, Hanhoff T, Van der Voort D, Arts B, Peters M, Ponds R, Honig A, Rudzinski W, Spener F, de Kruijk JR, Twijnstra A, Hermens WT, Menheere PP, Glatz JF (2004) Brain- and heart-type fatty acid-binding proteins in the brain: tissue distribution and clinical utility. Clin Chem 50:1568-1575
28. Provias J, Jeynes B (2011) Correlation analysis of capillary apoe, vegf and enos expression in alzheimer brains. Curr Alzheimer Res 8:197-202
29. Radebaugh T, Khachaturian ZS (1998) Consensus report of the working group on: "Molecular and biochemical markers of Alzheimer's disease". The Ronald and Nancy Reagan Research Institute of the Alzheimer's association and the National Institute on Aging Working Group. Neurobiol Aging 19:109-116
30. Roman GC (2004) Vascular dementia. Advances in nosology, diagnosis, treatment and prevention. Panminerva Med 46:207-215
31. Ruiz de Almodovar C, Lambrechts D, Mazzone M, Carmeliet P (2009) Role and therapeutic potential of VEGF in the nervous system. Physiol Rev 89:607-648
32. Shaw LM, Vanderstichele H, Knapik-Czajka M, Clark CM, Aisen PS, Petersen RC, Blennow K, Soares H, Simon A, Lewczuk P, Dean R, Siemers E, Potter W, Lee VM, Trojanowski JQ (2009) Cerebrospinal fluid biomarker signature in Alzheimer's Disease Neuroimaging Initiative Subjects. Ann Neurol 65:403-413
33. Shaw LM, Vanderstichele H, Knapik-Czajka M, Figurski M, Coart E, Blennow K, Soares H, Simon AJ, Lewczuk P, Dean RA, Siemers E, Potter W, Lee VM, Trojanowski JQ (2011) Qualification of the analytical and clinical performance of CSF biomarker analyses in ADNI. Acta Neuropathol 121:597-609
34. Sperling RA, Aisen PS, Beckett LA, Bennett DA, Craft S, Fagan AM, Iwatsubo T, Jack CR Jr, Kaye J, Montine TJ, Park DC, Reiman EM, Rowe CC, Siemers E, Stern Y, Yaffe K, Carrillo MC, Thies B, Morrison-Bogorad M, Wagster MV, Phelps CH (2011) Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for alzheimer's disease. Alzheimers dement 7:280-292
35. Steinacker P, Mollenhauer B, Bibl M, Cepek L, Esselmann H, Brechlin P, Lewczuk P, Poser S, Kretzschmar HA, Wiltfang J, Trenkwalder C, Otto M (2004) Heart fatty acid binding protein as a potential diagnostic marker for neurodegenerative diseases. Neurosci Lett 370:36-39
36. Storch J, Thumser AE (2010) Tissue-specific functions in the fatty acid-binding protein family. J Biol Chem 285:32679-32683
37. Storey JD, Tibshirani R (2003) Statistical significance for genomewide studies. Proc Natl Acad Sci USA 100:9440-9445
38. Tarkowski E, Issa R, Sjogren M, Wallin A, Blennow K, Tarkowski A, Kumar P (2002) Increased intrathecal levels of the angiogenic factors VEGF and TGF-beta in Alzheimer's disease and vascular dementia. Neurobiol Aging 23:237-243
39. Thambisetty M, Lovestone S (2010) Blood-based biomarkers of Alzheimer's disease: challenging but feasible. Biomark med 4:65-79
40. Trojanowski JQ, Vandeerstichele H, Korecka M, Clark CM, Aisen PS, Petersen RC, Blennow K, Soares H, Simon A, Lewczuk P, Dean R, Siemers E, Potter WZ, Weiner MW, Jack CR Jr, Jagust W, Toga AW, Lee VM, Shaw LM (2010) Update on the biomarker core of the Alzheimer's disease neuroimaging initiative subjects. Alzheimers dement 6:230-238
41. Veerkamp JH, Zimmerman AW (2001) Fatty acid-binding proteins of nervous tissue. J mol neurosci 16:133-142 discussion 151-137
42. Vidoni ED, Townley RA, Honea RA, Burns JM (2011) Alzheimer disease biomarkers are associated with body mass index. Neurology 77:1913-1920
43. Wagner M, Wolf S, Reischies FM, Daerr M, Wolfsgruber S, Jessen F, Popp J, Maier W, Hull M, Frolich L, Hampel H, Perneczky R, Peters O, Jahn H, Luckhaus C, Gertz HJ, Schroder J, Pantel J, Lewczuk P, Kornhuber J, Wiltfang J (2012) Biomarker validation of a cued recall memory deficit in prodromal Alzheimer disease. Neurology 78:379-386
44. Wunderlich MT, Hanhoff T, Goertler M, Spener F, Glatz JF, Wallesch CW, Pelsers MM (2005) Release of brain-type and heart-type fatty acid-binding proteins in serum after acute ischaemic stroke. J Neurol 252:718-724
45. Yang SP, Bae DG, Kang HJ, Gwag BJ, Gho YS, Chae CB (2004) Co-accumulation of vascular endothelial growth factor with beta-amyloid in the brain of patients with Alzheimer's disease. Neurobiol Aging 25:283-290
46. Zanier ER, Longhi L, Fiorini M, Cracco L, Bersano A, Zoerle T, Branca V, Monaco S, Stocchetti N (2008) Increased levels of CSF heart-type fatty acid-binding protein and tau protein after aneurysmal subarachnoid hemorrhage. Acta Neurochir Suppl 102:339-343
47. Zellner M, Veitinger M, Umlauf E (2009) The role of proteomics in dementia and alzheimer's disease. Acta Neuropathol 118:181-195
48. Zhang J, Sokal I, Peskind ER, Quinn JF, Jankovic J, Kenney C, Chung KA, Millard SP, Nutt JG, Montine TJ (2008) CSF multianalyte profile distinguishes Alzheimer and Parkinson diseases. Am j of clinical pathology 129:526-529
49. Zolg W (2006) The proteomic search for diagnostic biomarkers: lost in translation? Mol Cell Proteomics 5:1720-1726